|
1
|
Thompson CB and Jakubowski JA: The
pathophysiology and clinical relevance of platelet heterogeneity.
Blood. 72:1–8. 1988.
|
|
2
|
Thompson CB, Jakubowski JA, Quinn PG,
Deykin D and Valeri CR: Platelet size and age determine platelet
function independently. Blood. 63:1372–1375. 1984.
|
|
3
|
Smith NM, Pathansali R and Bath PM:
Platelets and stroke. Vasc Med. 4:165–172. 1999.
|
|
4
|
Endler G, Klimesch A, Sunder-Plassmann H,
et al: Mean platelet volume is an independent risk factor for
myocardial infarction but not for coronary artery disease. Br J
Haematol. 117:399–404. 2002.
|
|
5
|
O’Malley T, Langhorne P, Elton RA and
Stewart C: Platelet size in stroke patients. Stroke. 26:995–999.
1995.
|
|
6
|
Tschoepe D, Roesen P, Esser J, et al:
Large platelets circulate in an activated state in diabetes
mellitus. Semin Thromb Hemost. 17:433–438. 1991.
|
|
7
|
Mutlu H, Berk V, Karaca H, et al:
Treatment regimen with bevacizumab decreases mean platelet volume
in patients with metastatic colon cancer. Clin Appl Thromb Hemost.
18:546–548. 2012.
|
|
8
|
Inagaki N, Kibata K, Tamaki T, Shimizu T
and Nomura S: Prognostic impact of the mean platelet
volume/platelet count ratio in terms of survival in advanced
non-small cell lung cancer. Lung Cancer. 83:97–101. 2013.
|
|
9
|
Willett CG, Boucher Y, di Tomaso E, et al:
Direct evidence that the VEGF-specific antibody bevacizumab has
antivascular effects in human rectal cancer. Nat Med. 10:145–147.
2004.
|
|
10
|
Cohen RB and Oudard S: Antiangiogenic
therapy for advanced renal cell carcinoma: management of
treatment-related toxicities. Invest New Drugs. 30:2066–2079.
2012.
|
|
11
|
Elice F, Rodeghiero F, Falanga A and
Rickles FR: Thrombosis associated with angiogenesis inhibitors.
Best Pract Res Clin Haematol. 22:115–128. 2009.
|
|
12
|
Kuenen BC, Levi M, Meijers JC, et al:
Analysis of coagulation cascade and endothelial cell activation
during inhibition of vascular endothelial growth factor/vascular
endothelial growth factor receptor pathway in cancer patients.
Arterioscler Thromb Vasc Biol. 22:1500–1505. 2002.
|
|
13
|
Kuenen BC: Analysis of prothrombotic
mechanisms and endothelial perturbation during treatment with
angiogenesis inhibitors. Pathophysiol Haemost Thromb. 33:13–14.
2003.
|
|
14
|
Nalluri SR, Chu D, Keresztes R, Zhu X and
Wu S: Risk of venous thromboembolism with the angiogenesis
inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA.
300:2277–2285. 2008.
|
|
15
|
Choueiri TK, Schutz FA, Je Y, Rosenberg JE
and Bellmunt J: Risk of arterial thromboembolic events with
sunitinib and sorafenib: a systematic review and meta-analysis of
clinical trials. J Clin Oncol. 28:2280–2285. 2010.
|
|
16
|
Greisenegger S, Endler G, Hsieh K, et al:
Is elevated mean platelet volume associated with a worse outcome in
patients with acute ischemic cerebrovascular events? Stroke.
35:1688–1691. 2004.
|
|
17
|
Smith NM, Pathansali R and Bath PM:
Platelets and stroke. Vasc Med. 4:165–172. 1999.
|
|
18
|
Osada J, Rusak M, Kamocki Z, Dabrowska MI
and Kedra B: Platelet activation in patients with advanced gastric
cancer. Neoplasma. 57:145–150. 2010.
|
|
19
|
Cho SY, Yang JJ, You E, et al: Mean
platelet volume/platelet count ratio in hepatocellular carcinoma.
Platelets. 24:375–377. 2012.
|
|
20
|
Mutlu H, Artis TA, Erden A and Akca Z:
Alteration in mean platelet volume and platicrit values in patients
with cancer that developed thrombosis. Clin Appl Thromb Hemost.
19:331–333. 2013.
|
|
21
|
Braekkan SK, Mathiesen EB, Njølstad I,
Wilsgaard T, Størmer J and Hansen JB: Mean platelet volume is a
risk factor for venous thromboembolism: the Tromsø Study, Tromsø,
Norway. J Thromb Haemost. 8:157–162. 2010.
|
|
22
|
Scappaticci FA, Skillings JR, Holden SN,
et al: Arterial thromboembolic events in patients with metastatic
carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer
Inst. 99:1232–1239. 2007.
|
|
23
|
Hambleton J, Skillings J, Kabbinavar F, et
al: Safety of low-dose aspirin (ASA) in pooled analysis of 3
randomized, controlled trials (RCTs) of bevacizumab (BV) with
chemotherapy (CT) in patients (pts) with metastatic colorectal
cancer (mCRC). J Clin Oncol. 23:16S(abstr 3554). 2005.
|
|
24
|
Tebbutt NC, Murphy F, Zannino D, et al:
Australasian Gastro-Intestinal Trials Group: Risk of arterial
thromboembolic events in patients with advanced colorectal cancer
receiving bevacizumab. Ann Oncol. 22:1834–1838. 2011.
|
